June 30, 2020

InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

Model description:

In addition to sub-model describing virus and pneumocyte life cycles InSysBio team has constructed a sub-model describing life cycle of macrophages. Now we present the scheme of the sub-model and quality of calibration against in vivo baseline data. The sub-model describes:

• influx of monocytes (PBM) from bone marrow regulated by GMCSF,
• PBM migration to lung tissue stimulated by CCL2, CXCL10 and TGFb,
• PBM polarization to M1/M2 macrophages regulated by Antigen, IFNg, IL10, TGFb, IL4 and IL13,
• IL1b, IL6, IL10, IL12, IL23, TNFa, TGFb, CXCL10 and CCL2 production by the PBM and macrophages,
• cytokine/chemokine distribution between lung tissue, plasma and lymph node,
• cytokine chemokine degradation.

The model is preliminary calibrated against available in vitro data describing regulatory effects of cytokines/chemokines on cell dynamics and then finally calibrated against in vivo baseline data measured for healthy subjects.
To learn more about the model and detailed description of calibration, please, visit: https://github.com/insysbio/covid19-qsp-model

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

Share